Methoxy-9-ellipticine lactate in refractory acute myeloid leukaemia.
D000284:Administration, Oral; D000293:Adolescent; D000470:Alkaloids / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008738:Methyl Ethers / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors
D000470:Alkaloids; D000970:Antineoplastic Agents; D002227:Carbazoles; D008738:Methyl Ethers; D003561:Cytarabine; D015122:Mercaptopurine; D011241:Prednisone; D003630:Daunorubicin